Announcements Trials
Browse Landscape

Phase

Phase 4 3

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 1NIH 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Lymphoid 4Dermatologic 4

Conditions

Lymphoma, T-Cell, Cutaneous 4Neoplasms 3Lymphoma, T-Cell, Peripheral 3Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, B-Cell 2Recurrence 1Neoplasms by Histologic Type 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

mogamulizumab 4denileukin diftitox 4Vorinostat 4Panobinostat 4zanolimumab 3cobomarsen 3Brentuximab Vedotin 3Bexarotene 3tenalisib 2selinexor 2marizomib 2hypericin 2Vitamin B 12 2Rituximab 2Folic Acid 2A-dmDT390-bisFv(UCHT1) protein 210-propargyl-10-deazaaminopterin 2tislelizumab 1tinostamustine 1sapacitabine 1romidepsin 1resminostat 1quisinostat 1ontuxizumab 1navitoclax 1forodesine 1fludarabine phosphate 1enzastaurin 1belinostat 1abexinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, T-Cell, Cutaneous × denileukin diftitox × Clear all
NCT05137847 2023-12-12

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Eisai Inc.

Completed
118 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Drug-Related Side Effects and Adverse Reactions

NCT00050999 2008-03-05

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

Eisai Inc.

Phase 4 Completed
195 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00051012 2008-03-05

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Eisai Inc.

Phase 4 Completed
86 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00211198 2008-03-05

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Eisai Inc.

Phase 4 Completed
60 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡